Cantor Fitzgerald Forecasts Omeros FY2025 Earnings

Omeros Co. (NASDAQ:OMER) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Omeros in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer forecasts that the biopharmaceutical company will post earnings per share of ($1.73) for the year. Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for Omeros’ current full-year earnings is ($3.09) per share.

A number of other research analysts have also recently issued reports on OMER. Needham & Company LLC reissued a “hold” rating on shares of Omeros in a research report on Friday, January 17th. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a research report on Thursday, January 16th. Finally, Rodman & Renshaw initiated coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Three research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Trading Up 1.5 %

NASDAQ:OMER opened at $9.29 on Wednesday. The company has a 50-day moving average price of $9.55 and a 200-day moving average price of $6.10. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60. The stock has a market cap of $538.36 million, a price-to-earnings ratio of -4.02 and a beta of 2.01.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in OMER. Barclays PLC lifted its position in shares of Omeros by 121.3% during the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock valued at $376,000 after buying an additional 51,873 shares during the last quarter. State Street Corp lifted its position in shares of Omeros by 0.3% during the third quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock valued at $4,867,000 after buying an additional 3,839 shares during the last quarter. HighTower Advisors LLC lifted its position in shares of Omeros by 7.2% during the third quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company’s stock valued at $235,000 after buying an additional 4,000 shares during the last quarter. MML Investors Services LLC lifted its position in shares of Omeros by 19.2% during the third quarter. MML Investors Services LLC now owns 18,600 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 3,000 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new stake in shares of Omeros during the third quarter valued at about $305,000. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.